Keywords: Bristol-Myersd Squibb, Pfizer, Portola Pharma. Eliquis, PRT4445, Anticoagulant antidote

Bristol-Myers and Pfizer collaborate on Eliquis study with Portola's universal Factor Xa inhibitor antidote PRT4445

Article | 05 November 2012

Print This

Portola Pharmaceuticals, Bristol-Myers Squibb (NYSE: BMY) and Pfizer (NYSE: PFE) last week announced a clinical collaboration to conduct a ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in